TY - GEN
T1 - Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma
AU - Schachter, Jacob
AU - Katz, Uriel
AU - Mahrer, Arie
AU - Barak, Dov
AU - David, Liat Ziegel Ben
AU - Nusbacher, Jacob
AU - Shoenfeld, Yehuda
PY - 2007/9
Y1 - 2007/9
N2 - We have previously reported studies performed both in vitro and in laboratory animals, as well as a case study in humans, suggesting that intravenous immunoglobulin (IVIG) may be beneficial in the treatment of malignancies, including metastatic melanoma. As part of a phase II open label trial, we have administered IVIG to nine patients with metastatic melanoma who had been heavily treated. In two of nine (22%) patients treated every 3 weeks with IVIG (1 g/kg body weight), the disease stabilized. One patient had stable disease for 8 months; the other for 3 months. No serious adverse events (AEs) attributable to IVIG were observed. We conclude that IVIG therapy may be useful for the treatment of metastatic melanoma. Furthermore, we suggest that the effects of IVIG therapy might be enhanced by its use as an adjuvant in patients without evidence of disease following surgery.
AB - We have previously reported studies performed both in vitro and in laboratory animals, as well as a case study in humans, suggesting that intravenous immunoglobulin (IVIG) may be beneficial in the treatment of malignancies, including metastatic melanoma. As part of a phase II open label trial, we have administered IVIG to nine patients with metastatic melanoma who had been heavily treated. In two of nine (22%) patients treated every 3 weeks with IVIG (1 g/kg body weight), the disease stabilized. One patient had stable disease for 8 months; the other for 3 months. No serious adverse events (AEs) attributable to IVIG were observed. We conclude that IVIG therapy may be useful for the treatment of metastatic melanoma. Furthermore, we suggest that the effects of IVIG therapy might be enhanced by its use as an adjuvant in patients without evidence of disease following surgery.
KW - Adverse events
KW - Cancer
KW - IVIG
KW - Intravenous immunoglobulin
KW - Melanoma metastasis
UR - http://www.scopus.com/inward/record.url?scp=35748965294&partnerID=8YFLogxK
U2 - 10.1196/annals.1423.032
DO - 10.1196/annals.1423.032
M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.conference???
C2 - 17911445
AN - SCOPUS:35748965294
SN - 1573317098
SN - 9781573317092
T3 - Annals of the New York Academy of Sciences
SP - 305
EP - 314
BT - Autoimmunity, Part B Novel Applications of Basic Research
PB - Blackwell Publishing Inc.
ER -
